• $4.1M
    Market Cap
  • -100.00%
    1-Year Change
  • Biotechnology
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: N/A
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Propanc Biopharma is pursuing a strategic initiative to acquire Digital Asset Treasury (DAT) companies trading below their market cap to net asset value, aiming to diversify its asset base and create shareholder value.

11/04/2025, 7:00 AM • GlobeNewswire

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma secured a strategic financing agreement with Hexstone Capital for up to $100 million, involving convertible preferred stock and warrants to support clinical pipeline development and digital asset treasury strategy.

10/15/2025, 5:45 PM • GlobeNewswire

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma successfully closed a public offering of 1,000,000 shares at $4.00 per share, raising $4 Million and commencing trading on the Nasdaq Capital Market under the ticker PPCB.

08/19/2025, 8:30 AM • Benzinga

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Propanc Biopharma announced a public offering of 1 million shares at $4.00 per share, expecting to raise approximately $4 million. The company will use proceeds for working capital and has received approval to list on Nasdaq Capital Market.

08/14/2025, 11:00 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$1.62
$1.88
$1.64
1-Year Range
$0.07
$5.85
$1.64
Latest Close$1.64
Change
-$0.13 (-8.26%)
Volume15,177
Market Cap$4.1M
Shares Outstanding2.3M
P/E (TTM)0.51
Diluted EPS (TTM)$3.59
Enterprise Value$3.9M

Information as of 06/03/2026

Company Profile

PROPANC BIOPHARMA INC
https://www.propanc.com
$4.1M
Market Cap
-$19.3M
Net Income
Sector: Healthcare
Industry: Biotechnology
302, 6 Butler Street, Camberwell, VIC, Australia, 3124
61 3 9882 0780

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Key Executives

  • James Nathanielsz
  • Klaus Kutz
  • Jeannine Zimmerman

Current Ownership Distribution

  • Insiders24.3M (100.00%)
  • Institutions0 (0.00%)
  • Mutual Funds0 (0.00%)
  • Other0 (0.00%)